CaPtivate Pharmaceuticals

Product Development

Preclinical Development
Extensive preclinical data have been generated to demonstrate that CaP is safe and effective for both injection and for mucosal administration of both human and veterinary vaccines. Preclinical data indicated that CaP is able to induce both Th1- and Th2-type responses with most vaccine antigens and can induce local antibodies when administered mucosally. While we make our technology available for licensing per vaccine basis, we continue developing our CaP nanoparticle vaccine adjuvant technology (CaPtiVant^TM) with special focus on the following vaccine programs:

CaP-adjuvanted Influenza Vaccines
Influenza vaccines (seasonal influenza, H5N1 avian flu, and pandemic H1N1 swine flu strains) for injection or needle-free administration.
Intranasal HBsAg
Mucosal vaccine for hepatitis B for intranasal administration.
Mucosal Herpes Simplex-2 (HSV-2) Vaccine
Mucosal vaccine for herpes simplex-2 (HSV-2) for intravaginal administration.

While continue developing its vaccine program to address significant public health needs, CaPtivate is also making its CaP technology available through exclusive and non-exclusive licenses.